SPOTLIGHT -
EP. 1: Introduction: Biomarkers in Breast Cancer
EP. 2: Multigene Panel Testing in Breast Cancer
EP. 3: Tumor-Infiltrating Lymphocytes in Breast Cancer
EP. 4: Palbociclib in Metastatic Breast Cancer
EP. 5: Fulvestrant in HR-Positive Breast Cancer
EP. 6: Improving Endocrine Treatment Decisions in ER+ Breast Cancer
EP. 7: Overcoming Resistance in Breast Cancer
EP. 8: Clinical Trials for HER2-Positive Breast Cancer
EP. 9: Neratinib in HER2-Positive Breast Cancer
EP. 10: TNT Study for Triple-Negative or BRCA1/2 Breast Cancer
EP. 11: Future Approaches in Breast Cancer
Tusamitamab Ravtansine Plus Pembrolizumab With or Without Chemo Elicits Responses in CEACAM5+ NSCLC
Cemiplimab Monotherapy Induces Durable OS, PFS Benefits in PD-L1+ NSCLC With Brain Metastases
Four Cycles of Chemotherapy Plus Tremelimumab and Durvalumab Demonstrate Optimized Outcomes in Metastatic NSCLC
Taletrectinib Elicits Durable Responses in TKI-Naïve and Crizotinib-Pretreated ROS1+ NSCLC
